The ED5o of insulin-like growth factor (IGF)-I-stimulated aaminoisobutyric acid (AIB) uptake (mean±SD) in cultured fibroblasts from a child with short stature that we have reported (1.40±0.24 nM), is significantly higher than the ED50 of IGF-
Insulin-like growth factor I (IGF-I)' is a major mammalian postnatal growth factor that plays a key role in mediating the growth effects of pituitary growth hormone (1) . In responsive cells, IGF-I interacts at the plasma membrane with the IGF-I receptor, a heterotetrameric glycoprotein structurally homologous to the insulin receptor (2) . IGF 4) .
The sensitivity of target tissues to IGF-I may be an important determinant ofgrowth. Bierich et al. (5) reported that fibroblasts from a short child with growth failure bound 50% less '251I-labeled IGF-I than normal fibroblasts, although the structure and function of the IGF-I receptor in this child's fibroblasts were not directly examined. We have investigated IGF-I sensitivity in cultured skin fibroblasts from patients with short stature and have reported that fibroblasts from one child were significantly less responsive to stimulation by IGF-I in a-aminoisobutyric acid (AIB) uptake assays (6) . The ED_0s of IGF-Istimulated AIB uptake (mean±SD) in fibroblasts from 11 normal subjects (0.42±0.12 nM) and from 127 short children (0.35±0.11 nM) are similar (Heath-Monnig, E., D. P. Dempsher, and W. H. Daughaday, unpublished results) and significantly lower than the ED50 of IGF-I-stimulated AIB uptake in fibroblasts from this patient (1.40±0.24 nM). IGF-I binding to the patient's fibroblasts suspended by brief treatment with trypsin appeared to be normal, although interpretation of these studies was complicated since treatment of the cells with trypsin could potentially modify the IGF-I receptor and would remove adherent binding proteins (7, 8) .
In this study, we have used an IGF-I variant that interacts minimally with IGF binding proteins to examine fibroblast responsiveness. This variant, in which residues 3, 4, 15, and 16 have been changed from G3,T4,Q'5,F'6 to Q3,A4,Yl5,L16, has a 600-fold reduced affinity for serum binding proteins but an affinity for the IGF-I receptor that is equal to that of IGF-I (9) . The comparable biological activity ofthis IGF-I variant in nor-1. Abbreviations used in this paper: AIB, a-aminoisobutyric acid; CSC, child with short stature; IGF, insulin-like growth factor; IGFBP-1,2,3, IGF binding protein 1,2,3. mal and the patient's fibroblasts suggested that the resistance to IGF-I action in the patient's fibroblasts could not be attributed to a defective IGF-I receptor. We report here that IGF-I sensitivity in this patient's fibroblasts is reduced by an abnormal production of IGF binding proteins.
Methods
Materials. AIB, Hepes, polyethylene glycol (PEG) 8000, BSA, bovine gamma-globulins, nitroblue tetrazolium, 5-bromo-4-chloro-3-indolyl phosphate, NN-dimethylformamide, L-glutamine, and RPMI 1640 medium were purchased from Sigma Chemical Co., St. Louis, MO 20 Ci/mmol, were purchased from DuPont/ New England Nuclear Research Products, Boston, MA, and Na'25I, [13] [14] [15] [16] [17] '25I/Ilg I, was purchased from Amersham Corp., Arlington Heights, IL. FCS, DME, and MEM were routinely supplied by Gibco Laboratories, Grand Island, NY, and FCS was also obtained from J. R Ci/gmol) were prepared as previously described (10) .
Ascites fluid containing the MAb to the IGF-I receptor, aIR-3 (1 1), was kindly provided by Dr. Steven Jacobs (The Wellcome Research Laboratories, Research Triangle Park, NC). aIR-3 was affinity purified from the ascites fluid to remove IGF binding proteins using an EconoPac Protein A Kit, essentially as described by the manufacturer (BioRad Laboratories, Richmond, CA). Rabbit anti-human IGFBP-I antibody, raised against purified amniotic fluid IGFBP-1, and rabbit antihuman IGFBP-3 antibody (12), were kindly provided by Dr Fibroblast stock cultures were maintained in DME containing antibiotics (0.625 ,g/ml amphotericin B, 100 gg/ml penicillin G, 100 ,ug/ ml streptomycin sulfate) and 15% FCS, as previously described (6) . Experiments were performed on fibroblasts at passages 6-13, plated in DME containing antibiotics and 10% FCS. All the cultures were fed 3-4 d after plating. The cells were studied at confluency 6-9 d after plating.
The human hepatoma cell line HepG2, which produces IGFBP-1 (13) , and the human T helper cell line Jurkat, which produces IGFBP-2 (14) , were obtained from Dr. Richard Ostlund and Dr. Dennis Loh, respectively, at this institution. HepG2 cells were maintained in MEM containing antibiotics, 4 mM L-glutamine, and 10% FCS. Jurkat cells were maintained in MEM with 25 mM Hepes/RPMI 1640 medium (1: 1) containing antibiotics, 2 mM L-glutamine, and 10% FCS.
AIB uptake studies. AIB uptake assays were performed in 24-well clusters as previously described (6) , using an assay volume of 250 or 500 AI as indicated. Day 8 cell monolayers were used.
Thymidine incorporation studies. Thymidine incorporation assays were performed in 24-well clusters as described by Sasaoka et Affinity cross-linking analysis. Day 6 or 8 cell monolayers were vwashed three times with serum-free DME separated by 20-min incubations at 37°C, and affinity cross-linking analysis was performed as previously described (17) .
Collection offibroblast binding proteins. 0.5 x 106 cells were plated onto 100-mm plates in 10 ml DME containing antibiotics and 10% FCS in order to scale-up the incubation conditions used in the AIB uptake assay. Day 8 cell monolayers, untreated or pretreated for 2 d with serum-free medium at 37°C in room air, were used. The serumfree medium was collected, clarified by low speed centrifugation, and stored at -20°C until assayed. The monolayers were washed three times with Krebs-Ringer phosphate buffer, pH 7.37, with 5.5 mM glucose. 6 .55 ml of AIB assay buffer (Krebs-Ringer phosphate buffer, pH 7.37, with 5.5 mM glucose and 1 mg/ml BSA) was then added (corresponding to a 250-Al assay volume). After a 3 h incubation at 37°C in room air, the conditioned AIB assay buffer was removed, clarified by low speed centrifugation, and stored at -20°C until assayed. The cells were washed three times with Puck's Saline G and were solubilized in 500 Ml ofelectrophoresis sample buffer (62.5 mM Tris-HCI, pH For Western blot analysis, the blot was washed and incubated overnight at room temperature in TBS (50 mM Tris-HC1, pH 7.4, 200 mM NaCI) with 30 mg/ml BSA and 0.02% NaN3. Rabbit anti-human IGFBP-l antibody (1:10,000 dilution) in TBS with 10 mg/ml BSA was then added for 1.5 h. The blots were washed three times with TBS containing 0.1% NP-40 and 0.03% Triton X-100, once with TBS, and then incubated for 2 h with alkaline phosphatase-conjugated goat anti-rabbit IgG (1:5,000 dilution) in TBS with 10 mg/ml BSA. The blots were washed as described above, washed once with AP buffer (100 mM Tris-HCI, pH 9.5, with 100 mM NaCI, and 5 mM MgCl2), and developed using 66 pi of nitroblue tetrazolium (50 mg/ml in 70% N,N-dimethylformamide) and 33 MI of 5-bromo-4-chloro-3-indolyl phosphate (50 mg/ml in 100% NN-dimethylformamide) in 10 ml AP buffer. After 30 min, the blot was washed with PBS with 20 mM EDTA and dried.
IGF binding protein binding studies. IGF-I binding to secreted IGF binding proteins was determined as described by McCusker and Clemmons (21) . Briefly, conditioned AIB assay buffer was incubated with 123I-labeled IGF-I and increasing amounts of unlabeled IGF-I in 0.1 M Hepes, pH 6.0, with 44 mM NaH2PO4, 0.01% Triton X-100, 1 mg/ml BSA, and 0.02% NaN3 in 1.5 ml microfuge tubes. The final volume was 250 ,l. After a I-h incubation at room temperature, complexes ofbinding protein and IGF-I were precipitated at 4°C by the addition of250 Ml of0.4% bovine gamma-globulins in 0.1 M Tris-HCI, pH 7.4, and 500 M1 of25% PEG, followed by centrifugation in an Eppendorf microfuge for 15 min. The supernatant fluid was removed by aspiration, and the lower tip ofthe tube, containing the pellet, was excised and counted in a Micromedic 4/200 Automatic gamma counter. '251-labeled IGF-I binding was dependent on the amount of conditioned AIB assay buffer in the assay, and experimental results presented in this study were those obtained using amounts of conditioned AIB assay buffer at which the dose-dependent relationship was linear.
Methods of analysis. The data from competition binding studies were analyzed by LIGAND, a computer program developed by Munson and Rodbard (22) . The values reported for binding capacities and dissociation constants were obtained from a fit based on one class of sites since the improvement in fit by adding another class of sites was not substantial enough to warrant the additional complexity.
Results IGF-I stimulation ofAIB uptake and thymidine incorporation in normal and CSCfibroblasts. We have reported that fibroblasts from a child with short stature (CSC) were significantly less responsive to stimulation by IGF-I than fibroblasts from normal subjects (6) . Table I also 125I-labeled IGF-I binding to normal and CSC fibroblasts was inhibited 55% and 19%, respectively, by 2.3 jig/ml aIR-3, as shown in Fig. 2 A. In contrast, 125I-labeled [Q3,A4,Yl5,L'6]IGF-I binding to normal and CSC fibroblasts was inhibited 93% and 88%, respectively, by aIR-3, as shown in Fig. 2 B. Similar results were obtained in four other normal cell lines (data not shown).
The receptor to which IGF-I binds in these fibroblasts was determined by affinity cross-linking studies, as shown in Fig. 3 .
251I-labeled IGF-I was cross-linked predominantly to proteins that migrated under nonreducing conditions as complexes with apparent Mr > 300,000. These proteins correspond to the (afl)2, the (a3)(at), and the (af3)2 forms of the IGF-I receptor (28) . After reduction with 2-mercaptoethanol, these complexes migrated with an apparent M, 135,000 (see Fig. 7 B) . Cross- IGF binding proteins that were secreted into AIB assay buffer during a 3-h collection and that were cell-associated at the end ofthe collection were then analyzed by ligand blotting. As shown in Fig. 6 , the electrophoretic profile of IGF binding proteins secreted into AIB assay buffer in 3 h was similar to that secreted into serum-free medium over 2 d (see Fig. 4 Table I ). Ifi<> N P N P N P Figure 6 . Ligand blot of secreted and cell-associated IGF binding proteins in normal and CSC fibroblasts. AIB assay buffer (6.55 ml) was collected from untreated GM5565 (N) and CSC (P) fibroblasts after a 3-h incubation at 370C. The fibroblasts were then washed and solubilized in electrophoresis sample buffer (500 gl). Equivalent aliquots of conditioned AIB assay buffer (60 ,l) and of solubilized cells (4.5 jul) and a lOx aliquot of solubilized cells (45 ud) were analyzed by ligand blotting, as described in Methods. In this autoradiograph, the densitometric signal ofthe Mr 32,000 binding protein in the lOX aliquot of solubilized CSC cells was 10.9 times higher than that in the 1 X aliquot, confirming that the autoradiographic exposure gave densitometric signals in the linear range. The migration of prestained molecular weight standards is indicated.
of binding proteins that were cell-associated in CSC fibroblasts differed markedly from that ofsecreted binding proteins. Overall, by densitometric scanning of autoradiographs, we estimated that 1.8-2.9 times more binding protein was cell-associated in CSC fibroblasts than in normal (GM5565) fibroblasts. The major difference between normal and CSC fibroblasts was the striking amount of M, 32,000 binding protein that was cell-associated in CSC fibroblasts. (Fig. 7 B) , '251-labeled IGF-I was cross-linked to this binding protein and to the a subunit ( Fig. 8 A) and IGFBP-3 (see Fig. 4 ). It is also different from the major binding protein in human CSF, which is similar in size to IGFBP-2. Nevertheless, the M, 32,000 binding protein did not cross-react with an antibody against human IGFBP-1 (Fig. 8 B) . (34) and from a human HepG2 library (13) are nearly identical, these apparently conflicting results are not readily explained. It is possible that differences existed in the fibroblast lines used or in the specificities of the antibodies available in these studies. Alternatively, it is possible that the secretion of IGFBP-1 is developmentally regulated, since Hill et al. (32) reported that the ability of fibroblasts to secrete IGFBP-1 was related to cell density, being greatest in sparse cultures. The expression of IGFBP-2 in human fibroblasts has not been reported, but the mRNA expression of this binding protein in the rat has been shown to be highest in fetal tissues and greatly reduced in the corresponding adult tissues (35) . Martin and Baxter (30) reported that a ('25I-labeled IGF-II cross-linked) human fibroblast binding protein similar in size to IGFBP-1 could be immunoprecipitated using an antibody against IGFBP-3. This antibody (and an antibody against IGFBP-2 [37] ) have also been reported to cross-react with a binding protein in conditioned medium from the SV40-transformed human fibroblast line AG2804 (38) . We (39) reported that coincubation ofIGF-I with purified IGFBP-3 inhibited IGF-I-stimulated thymidine incorporation in human neonatal fibroblasts but that preincubation of fibroblasts with IGFBP-3 before adding IGF-I resulted in a potentiation of IGF-I action. The adherence of IGFBP-3 to the cell surface was not examined in these studies, although our study (see Fig. 7) and that of Clemmons et al. (8) suggest that a small amount of IGFBP-3 may adhere to the cell surface. Recent studies in human choriocarcinoma JEG-3 cells demonstrated that purified IGFBP-1 inhibited the maximal stimulation of AIB uptake by 10 ng/ml IGF-I (40), but 251I-labeled IGFBP-l alone or complexed to IGF-I did not bind to the JEG-3 cell surface in these studies. In contrast, Elgin et al. (41) reported that purified IGFBP-1 potentiated IGF-I stimulated DNA synthesis in human, mouse embryo, and chick embryo fibroblasts and porcine aortic smooth muscle cells. Subsequent studies revealed two forms ofthis binding protein with different biologic actions (42) . One form, designated peak B, enhanced IGF-I stimulation of [3H]thymidine incorporation into smooth muscle cell DNA, and a second form, peak C, prevented this response to peak B and IGF-I. Peak B was shown to adhere to cell surfaces whereas peak C did not. Further elucidation of IGF binding protein production and the regulation thereof in CSC fibroblasts may provide important insights into the physiological role of cell surface binding proteins in IGF action.
